2,851
edits
Line 48: | Line 48: | ||
=== Inhibiting Compounds === | === Inhibiting Compounds === | ||
Inhibiting compounds, or antagonists, are molecules that decrease the activity of SIRT6, offering a means to understand the functional importance of this enzyme in various cellular processes. These compounds typically bind to SIRT6 and reduce its enzymatic activity, which can be crucial for studying disease mechanisms or for developing therapeutic strategies targeting conditions where reduced SIRT6 activity might be beneficial. The inhibition of SIRT6 has been studied in the context of cancer biology, metabolic disorders, and other age-related diseases. In this section, we list compounds known to inhibit SIRT6, measured by their IC<sub>50</sub> values—the concentration at which they inhibit 50% of SIRT6's activity. Understanding these compounds provides insights into the regulatory mechanisms of SIRT6 and potential therapeutic avenues for diseases associated with its overactivity. | Inhibiting compounds, or antagonists, are molecules that decrease the activity of SIRT6, offering a means to understand the functional importance of this enzyme in various cellular processes. These compounds typically bind to SIRT6 and reduce its enzymatic activity, which can be crucial for studying disease mechanisms or for developing therapeutic strategies targeting conditions where reduced SIRT6 activity might be beneficial. The inhibition of SIRT6 has been studied in the context of cancer biology, metabolic disorders, and other age-related diseases. In this section, we list compounds known to inhibit SIRT6, measured by their [[IC50|IC<sub>50</sub>]] values—the concentration at which they inhibit 50% of SIRT6's activity. Understanding these compounds provides insights into the regulatory mechanisms of SIRT6 and potential therapeutic avenues for diseases associated with its overactivity. | ||
{| class="wikitable" | {| class="wikitable" |